Skip to content
Parakho

Fredun Pharmaceuticals Ltd

NSE FREDUNBSE 539730fredungroup.comInvestor relations

Statement of profit and loss

Parakho has not ingested a filed result for this company on a consolidated basis. When the company files one with the exchange, it appears here automatically.

Earnings call

Q4 FY26

Fredun Pharmaceuticals reported Q4 FY26 total income of INR213 crores, up 27.27% year-on-year, with EBITDA of INR29.13 crores and net profit of INR11.07 crores. For FY26, total income reached INR639.12 crores, a 40.08% year-on-year increase, with EBITDA of INR94.79 crores and net profit of INR33.21 crores. Management discussed growth plans for its hormonal, anti-aging, mobility, and pet care businesses, and addressed questions on raw material costs, finance costs, margins, and working capital.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 51 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 17 Aug 2026.